5 Stocks Pushing The Health Services Industry Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 39 points (-0.3%) at 13,960 as of Monday, Feb. 25, 2013, 11:49 AM ET. The NYSE advances/declines ratio sits at 1,475 issues advancing vs. 1,392 declining with 148 unchanged.

The Health Services industry currently sits down 0.1% versus the S&P 500, which is down 0.1%. Top gainers within the industry include Opko Health ( OPK), up 4.0%, Mindray Medical International ( MR), up 1.9%, Cooper Companies ( COO), up 1.6%, Agilent Technologies ( A), up 0.6% and Baxter International ( BAX), up 0.6%. On the negative front, top decliners within the industry include Smith & Nephew ( SNN), down 1.2%, and Intuitive Surgical ( ISRG), down 0.4%.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry higher today:

5. Quest Diagnostics ( DGX) is one of the companies pushing the Health Services industry higher today. As of noon trading, Quest Diagnostics is up $0.41 (0.7%) to $56.16 on heavy volume Thus far, 1.1 million shares of Quest Diagnostics exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $55.99-$56.60 after having opened the day at $56.16 as compared to the previous trading day's close of $55.75.

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. Quest Diagnostics has a market cap of $8.9 billion and is part of the health care sector. The company has a P/E ratio of 11.4, below the S&P 500 P/E ratio of 17.7. Shares are down 3.7% year to date as of the close of trading on Friday. Currently there is 1 analyst that rates Quest Diagnostics a buy, 2 analysts rate it a sell, and 14 rate it a hold.

TheStreet Ratings rates Quest Diagnostics as a buy. The company's strengths can be seen in multiple areas, such as its notable return on equity, good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Quest Diagnostics Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

4. As of noon trading, Edwards Life ( EW) is up $1.42 (1.6%) to $87.79 on average volume Thus far, 389,422 shares of Edwards Life exchanged hands as compared to its average daily volume of 990,500 shares. The stock has ranged in price between $86.54-$88.74 after having opened the day at $86.65 as compared to the previous trading day's close of $86.37.

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases or critically ill patients worldwide. Edwards Life has a market cap of $9.9 billion and is part of the health care sector. The company has a P/E ratio of 31.9, above the S&P 500 P/E ratio of 17.7. Shares are down 5.0% year to date as of the close of trading on Friday. Currently there are 9 analysts that rate Edwards Life a buy, 2 analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Edwards Life as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Edwards Life Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

3. As of noon trading, DaVita HealthCare Partners ( DVA) is up $0.97 (0.8%) to $117.02 on light volume Thus far, 290,107 shares of DaVita HealthCare Partners exchanged hands as compared to its average daily volume of 986,500 shares. The stock has ranged in price between $116.28-$117.47 after having opened the day at $116.54 as compared to the previous trading day's close of $116.05.

DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure, or end stage renal disease (ESRD) in the United States. DaVita HealthCare Partners has a market cap of $11.0 billion and is part of the health care sector. The company has a P/E ratio of 20.9, above the S&P 500 P/E ratio of 17.7. Shares are up 4.6% year to date as of the close of trading on Friday. Currently there are 10 analysts that rate DaVita HealthCare Partners a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates DaVita HealthCare Partners as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, increase in net income, good cash flow from operations and notable return on equity. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full DaVita HealthCare Partners Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

2. As of noon trading, Stryker Corporation ( SYK) is up $0.30 (0.5%) to $63.00 on light volume Thus far, 539,553 shares of Stryker Corporation exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $62.77-$63.17 after having opened the day at $62.82 as compared to the previous trading day's close of $62.70.

Stryker Corporation, together with its subsidiaries, operates as a medical technology company. The company operates in three segments: Reconstructive, MedSurg, and Neurotechnology and Spine. Stryker Corporation has a market cap of $23.6 billion and is part of the health care sector. The company has a P/E ratio of 18.3, above the S&P 500 P/E ratio of 17.7. Shares are up 14.4% year to date as of the close of trading on Friday. Currently there are 13 analysts that rate Stryker Corporation a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Stryker Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Stryker Corporation Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

1. As of noon trading, Covidien ( COV) is up $0.17 (0.3%) to $62.96 on light volume Thus far, 793,184 shares of Covidien exchanged hands as compared to its average daily volume of 2.2 million shares. The stock has ranged in price between $62.85-$63.56 after having opened the day at $63.07 as compared to the previous trading day's close of $62.79.

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. Covidien has a market cap of $29.4 billion and is part of the health care sector. The company has a P/E ratio of 15.8, below the S&P 500 P/E ratio of 17.7. Shares are up 7.8% year to date as of the close of trading on Friday. Currently there are 15 analysts that rate Covidien a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, attractive valuation levels, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Covidien Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

null